SHR-8068 combined with other cancer drugs for advanced kidney cancer
Tests SHR-8068 with other anti-cancer drugs in adults with advanced renal cell carcinoma.
Plain-language title generated from the registry record
Registry title: Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07239596, who can take part
Where in China
- Beijing Cancer HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Trial code
- NCT07239596
- Record updated
- 11 August 2026
- Original description
This study evaluated the safety and efficacy of SHR-8068 in combination anti-tumor drugs in the treatment of advanced renal cell carcinomaRead full original descriptionShow less
An Open, Multicenter Phase Ib/II Clinical Study of SHR-8068 in Combination Anti-tumor Drugs for the Treatment of Advanced Renal Cell Carcinoma
This study evaluated the safety and efficacy of SHR-8068 in combination anti-tumor drugs in the treatment of advanced renal cell carcinoma
Inclusion: Age 18 to 75 years old (including boundary values); Volunteer to participate in this clinical study and sign informed consent; ECOG score 0-1; Expected survival ≥3 months; Patients with locally advanced unresectable or metastatic clear cell renal cell carcinoma confirmed by histology or cytology; Tumor tissue samples must be provided for testing; There is at least one measurable or evaluable lesion that meets the RECIST 1.1 criteria; Adequate bone marrow and organ function.
Exclusion: Have previously used or are currently using HIF inhibitors; Had received chemotherapy, immunotherapy, targeted therapy, anti-tumor traditional Chinese medicine or other clinical research drugs within 4 weeks prior to the first administration of the study; Palliative radiotherapy was received within 2 weeks before the first administration; Live attenuated vaccines are used within a certain period of time before the first medication as stipulated in the plan, or it is expected that such vaccines will be needed during the treatment period; Undergoing major surgical treatment within a certain period of time after the first administration of medication (excluding diagnosis) or expecting major surgical treatment during the study period; There are severe gastrointestinal function abnormalities in clinical practice, which may affect the intake, transportation or absorption of drugs; Patients who have received organ transplants in the past (excluding corneal transplants); A clinically significant thrombotic or embolic event occurred within 6 months prior to the first administration of the drug; The toxicity and/or complications of previous intervention measures have not been restored to the level of NCI-CTCAE≤1 or the inclusion and exclusion criteria; Suffering from other active malignant tumors within 3 years or at the same time; There are clinical symptoms or diseases of the heart that are not well controlled; Active tuberculosis; Subjects with active hepatitis B or active hepatitis C; Moderate and severe ascites with clinical symptoms; Uncontrolled or moderate to excessive pleural effusion and pericardial effusion; As determined by the researcher, there are other factors that may affect the research results or lead to the forced termination of this study midway.